We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

204 hedge funds and large institutions have $1.1B invested in Sage Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 61 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more call options, than puts

Call options by funds: $5.76M | Put options by funds: $3.67M

17% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 24

15% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 61

2.38% more ownership

Funds ownership: 94.92% → 97.3% (+2.4%)

2% more funds holding

Funds holding: 200 → 204 (+4)

11% less capital invested

Capital invested by funds: $1.23B → $1.1B (-$138M)

Holders
204
Holders Change
+4
Holders Change %
+2%
% of All Funds
2.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
70
Reduced
61
Closed
24
Calls
$5.76M
Puts
$3.67M
Net Calls
+$2.09M
Net Calls Change
-$5.32M

Top Buyers

Rank Fund Capital Flow
1
BG
Bellevue Group
Switzerland
+$22M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$14.8M
3
State Street
State Street
Massachusetts
+$13.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$9.96M
5
BBA
Baker Bros. Advisors
New York
+$9.39M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$30.2M
2
CAC
Cowen and Company
New York
-$20.9M
3
JP Morgan Chase
JP Morgan Chase
New York
-$11.9M
4
Morgan Stanley
Morgan Stanley
New York
-$11.2M
5
Citadel Advisors
Citadel Advisors
Florida
-$6.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$7.25M -$617K -26,766 -6%
Hudson Bay Capital Management
27
Hudson Bay Capital Management
Connecticut
$7.03M -$461K -20,000 -5%
Ameriprise
28
Ameriprise
Minnesota
$6.74M +$1.17M +50,800 +16%
Citigroup
29
Citigroup
New York
$6.31M +$4.89M +212,110 +171%
Two Sigma Investments
30
Two Sigma Investments
New York
$6.16M +$1.84M +79,875 +32%
Millennium Management
31
Millennium Management
New York
$5.64M -$739K -32,050 -10%
PA
32
Pinnacle Associates
New York
$5.36M +$2.71M +117,344 +70%
SFM
33
Soros Fund Management
New York
$5.15M +$6.34M +275,000 New
American Century Companies
34
American Century Companies
Missouri
$5.03M +$2.16M +93,547 +54%
Norges Bank
35
Norges Bank
Norway
$4.8M -$836K -36,242 -12%
UBS Group
36
UBS Group
Switzerland
$4.78M +$1.2M +52,022 +26%
JFG
37
Jefferies Financial Group
New York
$4.46M +$2.52M +109,269 +85%
CS
38
Candriam SCA
Luxembourg
$4.16M -$115K -5,000 -2%
Jane Street
39
Jane Street
New York
$3.83M +$3.13M +135,497 +196%
IHAM
40
Integral Health Asset Management
New York
$3.75M – – –
6CM
41
683 Capital Management
New York
$3.75M +$4.61M +200,000 New
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$3.69M -$3.21M -139,007 -41%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$3.39M -$340K -14,758 -8%
Citadel Advisors
44
Citadel Advisors
Florida
$3.01M -$6.29M -272,582 -63%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$2.99M -$2.2M -95,329 -37%
Assenagon Asset Management
46
Assenagon Asset Management
Luxembourg
$2.93M +$3.3M +143,075 +1,058%
GIM
47
Granahan Investment Management
Massachusetts
$2.93M +$3.61M +156,371 New
PP
48
PDT Partners
New York
$2.69M -$125K -5,406 -4%
N
49
Nuveen
North Carolina
$2.67M – – –
Verition Fund Management
50
Verition Fund Management
Connecticut
$2.63M +$183K +7,949 +6%
1
2
3 4 5

SAGE Hedge Fund Activity: Q1 2024 in Review

204 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2024, worth a combined $1.1B — down 11% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new SAGE positions and 24 closed out — a net gain of 4 holders — while 70 added to existing stakes and 61 trimmed.

The largest buyer was Bellevue Group, adding an estimated $22M. The largest seller was Wellington Management Group, cutting an estimated $30.2M.

  • 204 institutional investors held Sage Therapeutics (SAGE) as of Q1 2024, up from 200 in Q4 2023.
  • Funds reported $1.1B of Sage Therapeutics stock for Q1 2024, down 11% quarter-over-quarter.
  • 28 funds opened new Sage Therapeutics positions in Q1 2024 and 24 closed out, a net change of +4 holders.
  • The largest Sage Therapeutics buyer in Q1 2024 was Bellevue Group, an estimated $22M added.
  • The largest Sage Therapeutics seller in Q1 2024 was Wellington Management Group, an estimated $30.2M sold.

Based on aggregated 13F filings for Q1 2024.